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Diabetic ketoacidosis (DKA) remains one of the most frequently encountered 
diabetes related emergencies, and despite updates in management and increasing 
standardisation of care, still has an appreciable morbidity and mortality. This review 
focusses on the pathophysiology and epidemiology of DKA, but also on the 
importance of having a standardised definition. 
Methods
Relevant data were reviewed where there was available basic science or clinical 
papers published in peer-reviewed international journals on DKA. These included 
consensus documents and national or international guidelines
Results
The prevalence of DKA varies around the world, but part of this could be down to the 
way the condition is defined. Examples of this difference include the recent studies 
on sodium glucose co-transporter inhibitors in people with type 1 and type 2 diabetes 
which have all been associated with increased rates of DKA, but have highlighted 
how differences in definitions can make comparisons between agents very difficult.
Conclusions.
DKA should only be diagnosed when all three components are present – the ‘D’, the 
‘K’ and the ‘A’. In addition, the definitions used to diagnose DKA should be 
standardised – in particular for clinical trials. 
  
Introduction
Diabetic ketoacidosis (DKA) occurs most commonly as a result of absolute or 
relative insulin deficiency and remains one of the most frequent causes of death in 
children and young adults with type 1 diabetes. Whilst DKA occurs most frequently in 
those with type 1 diabetes, it can occur in people with type 2 diabetes or gestational 
diabetes. There has been a resurgence of interest in DKA over the last few years 
due to it developing with increased frequency in people taking sodium glucose co-
transporter (SGLT) inhibitors. In particular, recently published trials using these 
agents in people with type 1 diabetes have shown a significant risk of developing 
DKA. Thus there is a pressing need to be able to diagnose and treat this condition 
appropriately. To date, however, direct comparisons of the how frequently DKA 
develops using a particular agent has proved impossible because the trials all used 
different definitions.
Pathophysiology
Depending on the circulating concentration, insulin has several effects; at the very 
lowest concentrations, insulin inhibits lipolysis and thus switches off ketone 
production. At increasingly higher concentrations insulin stimulates the uptake of 
glucose into the cells, inhibits glycogenolysis and stimulates glycogen synthesis [1]. 
Thus if insulin is absent, or if concentrations of counter-regulatory hormones – 
cortisol, catecholamines or glucagon – are high, such as at times of acute illness, 
then insulin mediated cellular glucose uptake is reduced, necessitating the provision 
of an alternative energy substrate. 
  
Insulin deficiency results in an increase in the activity of hormone sensitive lipase. 
This leads to triglyceride breakdown and free fatty acid liberation [2]. These free fatty 
acids form acetyl coenzyme A (CoA) due to beta oxidation, and enter the 
tricarboxylic acid (TCA) cycle. However, when free fatty acid concentrations are high, 
as with insulin deficient states, then the TCA cycle is overwhelmed and the acetyl 
CoA is instead converted to ketone bodies in the liver [3]. These ketone bodies enter 
the circulation primarily as β-hydroxybutyrate (which is, strictly speaking, a hydroxyl 
acid but referred to from here on as a ketone body) and acetoacetate at an 
approximate ratio of 10:1 [4]. Figure 1 illustrates how the raised concentration of free 
fatty acids due to increased lipolysis leads to a rise in CoA concentrations, which 
then acts as the precursor for hepatic production of beta-hydroxybutyrate, 
acetoacetate, and acetone.
In the clinical setting, the accumulation of these ketone bodies results in the high 
anion gap metabolic acidosis seen in DKA, but it is important to ensure that the high 
anion gap is not due to other causes of ‘fixed acid’ retention – e.g. ethylene glycol or 
methanol ingestion, lactate or 5-oxoproline accumulation, aspirin overdose, 
rhabdomyolysis, renal failure and ketoacidosis from other causes, e.g. liver disease.
Causes of DKA
The most common causes of this potentially life threatening condition are infection, 
intercurrent illness, poor adherence to prescribed medications and failure of 
technology, e.g. pump malfunction or faulty injection device [5,6]. Most cases occur 
in those with type 1 diabetes, but in some regions DKA in people type 2 diabetes 
accounts for up to 50% of cases, depending on family history and ethnicity [7,8]. 
  
Other reports suggest that it is fragmentation of care, and lack of continuity that 
contribute to episodes of recurrent DKA – and increased DKA associated mortality 
[9]. Other factors contributing to recurrent admissions were the presence of co-
morbidities, such as end stage renal failure, drug or alcohol misuse, non-
concordance with insulin therapy, mental health disorders and discharge against 
medical advice [10,11]. Over 40% of cases may be readmitted within 2 weeks of 
discharge [10].
Previous work has suggested that DKA in adults is the presenting feature in up to 
30% of new cases of type 1 diabetes [12-17], but this may be as high as 80% for 
children [18]. Recent data from the UK suggests that in adults, 30% may be an 
overestimate, with a new diagnosis of type 1 diabetes only occurring in 3-6% of 
cases [6,19]. 
Epidemiology – prevalence, mortality and cost
The prevalence of DKA also varies across the world. In North America, the most 
recent data from the type 1 diabetes exchange registry suggests that - for those 
looked after in specialist centres - the rate is 3% every 3 months [20]. This is in 
contrast to previous data suggesting rates between 1% and 5%, equating to 145,000 
cases per year [12,21]. More recent figures from the US Department of Health and 
Human Services / Centers for Disease Control and Prevention suggest that between 
2009 and 2014 the rates of DKA rose from 19.5 to 30.2 per 1000 patient years with 
no clear explanation why this may be the case [22]. In the UK the reported rates are 
about 3.6%, equating to 48 episodes per 1000 patient years [23], similar to previous 
data from elsewhere in Northern Europe [24-26]. Data from the UK suggested that 
  
rates of hospital admission with DKA have risen between 1997 and 2013 [27]. For 
those with type 1 diabetes there was a marked rise starting in 2004 rising from 
approximately 28 per 1000 patient years, to approximately 43 per 1000 patient years 
by 2007 – an annual percentage change of 14.1, whereas for those with type 2 
diabetes, there has been a steady rise in incidence from 1997 to 2013 from 0.6 to 
1.0 per 1000 patient years, an annual percentage change of 4.24 [27]. However, 
more recent data from Germany suggests that overall rates have decreased slightly 
to 25 per 1000 patient years, with the highest rates in those aged 18-30 years old 
[28]. Rates are reported to be much higher in the Western Pacific at 100 per 1000 
patient years in children [29]. Recent work has suggested that in children and 
adolescent, there is a relationship between the development of DKA and a country’s 
level of development, i.e. the highest rates occur in least developed nations [30].
Mortality in DKA varies across the world. In the US, data from the Centres for 
Disease Control and others suggest that mortality declined between 2000 and 2014 
from 1.1% to 0.4% whilst in the UK, mortality has also been reported at <1% 
[6,22,31,32]. In India however in-hospital mortality may be as high as 30% [33].
Treatment of DKA is expensive, with costs in the USA estimated to be in the region 
of $26,566 per episode [32], but in the UK this is £2,064 for adults and £1,387 in 
adolescents [34,35]. These costs are relevant, because in those health economies 
where the individual has to pay for their own care, treatment regimens may vary 
according to biochemical and clinical severity. An example of this is the United 
States, where some cases of ‘mild’ DKA may be treated as an outpatient using 
subcutaneous insulin regimens [36,37].
  
Definition
In the UK, the diagnosis of DKA in adults requires all three components to be 
present. The ‘D’ – means that the individual must have either a glucose 
concentration of >200mg/dl (11.1mmol/l) at the time of presentation, or have been 
previously diagnosed with diabetes. The ‘K’ means they must have plasma beta-
hydroxybutyrate concentrations of ≥3.0mmol/l, or urine ketones of more than 2+ on a 
standard urine ketone stick. The ‘A’ means they must have a pH<7.3 or a serum 
bicarbonate of <15.0mmol/l [38]. This definition is very similar to that advocated by 
the International Society of Pediatric and Adolescent Diabetes (ISPAD) [39]. The 
threshold ketone concentration of >3.0mmol/l came from a small study of 20 people, 
of whom 14 had presented with DKA. In their analysis of the β-hydroxybutyrate 
concentrations on admission, they worked out that concentrations of <1.0mmol/l 
were not associated with the development of DKA, those between 1.0 and 
<3.0mmol/l required repeated monitoring and those who had a ketone concentration 
of ≥3.0mmol/l required medical attention [40]. These data may no longer be up to 
date, and further work is needed to ensure they are correct. 
The UK definition is different from that advocated in 2009 by the American Diabetes 
Association (ADA) [41]. However, there have been recent calls for the ADA guideline 
to be updated because it is no longer felt to be fit for purpose, in particular with the 
increased incidence of euglycaemic DKA seen with the use of the sodium glucose 
co-transporter (SGLT) inhibitors [42,43]. The 2009 ADA guideline starts by stating 
that to diagnose DKA, the glucose must be ≥250mg/dl (13.9mmol/l). More recently, 
however, there has been recognition that the ADA definition was no longer 
  
appropriate, and a joint consensus document from a number of organisations 
including the ADA, American Association of Clinical Endocrinologists, the American
Association of Diabetes Educators, the Endocrine Society, Juvenile Diabetes 
Research Foundation, Pediatric Endocrine Society, and the T1D Exchange 
suggested that a new definition be adopted [44]. This stated that DKA be diagnosed 
when urine or serum ketone concentrations were above the upper limit of the 
reference range, and when bicarbonate concentrations were <15mmol/l or a pH 
<7.3. Glucose is not part of their diagnostic criteria. However, this definition is 
potentially contentious because an anion gap is not included and thus does not 
account for an acidosis due to other causes. In addition, if the upper limit of ketones 
is 0.6mmol/l, any higher values could potentially lead to an over-diagnosis of DKA 
[44]. 
Further data are emerging from several sources suggesting that significant numbers 
of people presenting with DKA whilst taking SGLT inhibitors - 71% according to the 
Food and Drug Administration (FDA) Adverse Event Reporting System - present with 
a glucose concentration between 150-250mg/dl (8.3-13.9mmol/l) – a condition 
known as euglycaemic DKA. Therefore these criteria clearly need revising [45-48]. 
Measurement of ketones
Blood ketone concentrations should be monitored in preference to urinary ketones. 
The reasons for this are discussed in detail elsewhere [49], but include that the 
predominant ketone in the blood is β-hydroxybutyrate whilst the predominant ketone 
in the urine is its breakdown product, acetoacetate. Thus, measuring only urine will 
give a false reading as to the time taken to achieve biochemical resolution. In 
  
addition, ketones in the urine only become apparent when urine is passed, and in a 
person who is dehydrated, this may be several hours [49]. 
Euglycaemic DKA
This condition was first described in 1973 where the authors described how 17.5% of 
211 people presenting with DKA had an initial glucose concentration at presentation 
of <300mg/dl (16.7mmol/l) [50]. Twenty years later, another group of authors 
reported that in 722 episodes of DKA, 3.2% has euglycaemic DKA using the same 
glucose threshold, but this dropped to 0.8-1.1% if the glucose cut- off value was 
180mg/dl (10.0mmol/l) [51]. The current ADA guidelines cite a further reference, and 
quote a prevalence of 10% for those presenting with a glucose of <250mg/dl 
(13.9mmol/l) [41,52]. Data from a national and local survey carried out in 2014 and 
2015 in the UK (i.e. prior to the widespread use of SGLT inhibitors) suggest that in 
adults, the rates of euglycaemic DKA were 3%, 5.4% and 8.7% when using 
admission glucose thresholds of <200mg/dl (11.0mmol/l), <250mg/dl (13.9mmol/l), 
and <300mg/dl (16.7mmol/l) respectively [6,53,54]. 
The pathogenesis of euglycaemic DKA is thought to be somewhat different to 
hyperglycaemic DKA, with a lesser degree of insulin deficiency/resistance leading to 
lower excess glucose production and higher glucose disposal. There are data to 
suggest that renal glucose clearance is higher in this condition than with 
hyperglycaemic DKA [55]. Euglycaemic DKA can occur in a number of other 
conditions such as pregnancy, where the foeto-placental unit utilises glucose leading 
to lowered insulin requirement. This leads to higher free fatty acid production thus 
leading to ketosis in the presence of low glucose. Physiological ketonaemia occurs in 
  
starvation or deceased carbohydrate intake, but an inability to produce endogenous 
carbohydrate, e.g. with glycogen storage disease or inborn errors of metabolism, 
alcoholism, or severe liver disease can also lead to high ketone concentrations. 
These conditions are considered in more detail elsewhere [56].
Given the lower glucose in euglycaemic DKA, the only major difference in treatment 
would be the earlier use of a dextrose containing fluid as the substrate for the insulin 
infusion in addition to the 0.9% sodium chloride solution given as the resuscitation 
fluid. 
SGLT inhibitor use and DKA
The use of these agents is undoubtedly associated with an increased risk of 
developing DKA, even in those with type 2 diabetes [45-48]. In the trials using SGLT 
inhibitors in people with type 1 diabetes, the reported rates of DKA were much higher 
in the drug arms than for those in the placebo arms. For those on empagliflozin 
2.5mg the rate was 0.8%, on 10mg it was 4.3%, and for 25mg it was 3.3%, 
compared to a rate on placebo of 1.2%, equating to rates of 59.4, 50.5 and 17.7 
events per 1000 patient years respectively [57]. The rates for dapagliflozin was 2.6% 
or 4% on 5mg (58.3 or 47.6 events per 1000 patient years), on 10mg the rates were 
2.2% or 3.4% (49.9 or 36.7 events per 1000 patient years), compared with rates of 
up to 1.9% on placebo (21.5 events per 1000 patient years) [47,58]. For sotagliflozin 
200mg the rates were 2.3% or 3.4%, and for the 400mg dose, the rates were 3.0% 
or 3.4% (30 or 34 events per 1000 patient years), compared with rates on placebo of 
0.0%-0.6% (0 to 3.8 events per 1000 patient years) [59-62]. These episodes 
occurred despite the robust risk mitigation strategies in place. The lower rates in the 
  
placebo arms of the trials compared to previously published rates suggested that 
these risk mitigation strategies worked. However despite these being in place, DKA 
occurred 2.3 – 5.6 times more frequently with the use of the SGLT inhibitors. If one 
were to extrapolate the rates to that seen in the ‘real-world’ literature where the risk 
mitigation may not be as rigorously enforced, then the argument against their use is 
that DKA rates may increase to between approximately 140 and 270 cases per 1000 
patient years in adults. As an illustration, in their analysis of the data submitted for 
sotagliflozin approval, the US FDA calculated the number needed to harm of 
between 205 and 311 per 1000 patient years [48]. Whilst the FDA issued a complete 
response letter for sotagliflozin, indicating that the drug cannot be approved in its 
current form [63], in January 2019 the European Medicines Agency recommended a 
change to the terms of the marketing authorization for dapagliflozin allowing it to be 
used as an “adjunct to insulin in patients with BMI ≥ 27 kg/m2, when insulin alone 
does not provide adequate glycaemic control despite optimal insulin therapy” [64]. 
The impact of this decision remains uncertain given the increased DKA risk. 
One of the main concerns with the incidence data however, is that that there has 
been no standardised definition used across clinical trials where DKA was a clinical 
risk. This makes direct comparison of DKA incidence rates between agents 
impossible [47,57,60,61]. This is illustrated by the DKA data from the canagliflozin 
studies where the investigators reported 12 cases of DKA across their trail 
programme [65]. However, their data has been criticised because of their twelve 
cases of ‘DKA’ 1 did not have a glucose, 6 did not have a pH, 5 did not have a 
bicarbonate measurement, 10 did not have an anion gap and 7 did not have ketones 
measured [66]. 
  
The empagliflozin study used a wide variety of ‘a priori’ definitions [57]. The authors 
suggested that DKA was certainly present if the pH was ≤7.3 and blood β-
hydroxybutyrate of >1.5mmol/l and urine ketones ‘≥++’. It was also present even if 
the pH was unavailable but the bicarbonate was <15.0mmol/l, blood β-
hydroxybutyrate of >1.5mmol/l and urine ketones ‘≥++’. The authors described ++ or 
+++ urine ketones as ‘moderate’ or ‘large’, translating to a blood β-hydroxybutyrate 
concentration of 1.5-2.9mmol/l. ++++ urinary ketones was described as ‘very large’, 
and equivalent to ≥3.0mmol/l of β-hydroxybutyrate. Cases were described as 
‘potential DKA’ if the pH was ≤7.3, with a suggestive history (e.g. pump failure, 
missed insulin doses, intercurrent illness, incorrect implementation of sick day rules, 
etc.). Alternatively pH was ≤7.3 and typical symptoms were also present, then this 
could also be defined as ‘potential DKA’. Such symptoms included confusion, 
reduced conscious level or drowsiness, dehydration, Kaussmaul breathing, 
abdominal pain, nausea or vomiting. Potential DKA was also defined if the pH were 
not available, but the bicarbonate was ≤18.0mmol/l, and suggestive signs or 
symptoms were present, or if the serum bicarbonate was 15.0-18.0mmol/l, together 
with blood β-hydroxybutyrate concentration of >1.5mmol/l with urinary ketones of 
≥++. In this combination, signs and symptoms were not necessary, unlike if the pH or 
bicarbonate were unavailable, but the blood β-hydroxybutyrate concentration was 
>1.5 and urinary ketones were ≥++. The final ‘potential DKA’ category was no pH, no 
bicarbonate, but a blood β-hydroxybutyrate concentration of >3.8mmol/l with urinary 
ketones of ++++. 
  
The cases that were adjudicated as ‘unlikely DKA’ had a blood β-hydroxybutyrate 
concentration of ≤1.5mmol/l and/or a pH >7.3, or if the pH was unavailable, a 
bicarbonate concentration of >18.0mmol/l. Those individuals who had a blood β-
hydroxybutyrate concentration of >1.5 and <3.8mmol/l and a pH>7.3, or a 
bicarbonate of >18.0mmol/l if the pH was unavailable, were classified as ‘unlikely 
DKA but ketosis’. If only a pH of ≤7.3, or a bicarbonate of ≤18.0mmol/l or only 
symptoms or signs were present then they were ‘unclassifiable’.
The dapagliflozin studies used the ADA guideline [41] “but without the requirement 
for hyperglycaemia” [58]. The sotagliflozin studies definition was based on the ADA 
guideline [41] - i.e. “anion-gap metabolic acidosis related to excessive ketone 
production without a satisfactory alternative cause for anion-gap acidosis”. They 
went on to say that “However, final diagnosis of metabolic acidosis, including 
diabetic ketoacidosis, was made by the adjudication committee.” [59]. Furthermore, 
the adjudication committee classified the events as “Yes, with certainty”, “Yes, 
probably”, “No, unlikely”, “No, with certainty”, “Unclassifiable”, or “Insufficient data”. 
[60]. 
These definitions were all subtly different from the – relatively straightforward – UK 
guideline from the Joint British Diabetes Societies which is also widely used, i.e. 
ketonaemia > 3.0mmol/l or significant ketonuria (more than 2+ on standard urine 
sticks) AND, a blood glucose > 11.0mmol/l (200mg/dl) or known diabetes mellitus 
AND a bicarbonate (HCO3-) < 15.0mmol/l and/or venous pH < 7.3 [38]. 
The definition of DKA needs to be standardized
  
What these trials show is the heterogeneity surrounding definitions. Not only that, 
what access different institutions have to the tests used to diagnose DKA needs to 
be consistent. There has been a previous call to standardise the definition of DKA to 
avoid the current – confusing – situation [43]. But to allow the definitions to be 
standardised, there needs to be an agreement on what criteria to use – especially in 
the clinical trial setting. A blood gas analyser is a common finding in many hospitals, 
thus the ‘D’, the ‘K’ and the ‘A’ need to be measured in order to make a diagnosis. A 
capillary (or plasma) glucose should be readily available. A blood β-hydroxybutyrate 
concentration – either bedside using a point of care meter, or laboratory 
measurement should be taken. A previous review has described the disadvantages 
of using urine ketones in the management of DKA [49]. A venous (not arterial) pH 
and bicarbonate measurement should be the minimum standard that pharmaceutical 
companies and others should insist on being measured when DKA is suspected 
because the differences between arterial and venous values are not significantly 
different enough to affect patient management [67,68]. In addition, the anion gap 
should be high, with no other attributable cause. The anion gap is a relatively easy 
calculation from standard blood tests of renal function ([Na+] - ([Cl-] + [HCO3-])) – the 
potassium can be added to the anion side of the equation, but is often not high 
enough to affect an individuals’ management. However, the need to identify a high 
anion gap means that chloride measurement needs to be available. Indeed, trial 
sites should only be used when these facilities and measurements are routinely 
available.
  
It is acknowledged however, that filling these diagnostic gaps remains aspirational, 
because there are little data to suggest that not having them is associated with harm. 
However, for centres involved in clinical trials these should be mandatory.
Clinical context
For many clinicians treating DKA ‘at the front door’ the subtleties of a standard 
definition for DKA may be lost – the simple message of ensuring DKA is diagnosed 
when someone has a raised glucose (or a history of diabetes), a raised ketone 
concentration and an acidosis should prompt urgent treatment. In addition, other 
situations, such as euglycaemic DKA or keto-alkalosis following excessive vomiting 
should be recognised and treated. What remains unknown however, is does using 
these very small differences in definitions lead to different outcomes. As always, 




Prior to the discovery of insulin in 1921, type 1 diabetes was universally fatal, most 
frequently due to DKA. Even with the many advances in care over the last few 
decades there remain many challenges in the management of this condition. Whilst 
the principles of treatment remain unchanged with fluids, insulin and electrolyte 
replacement, DKA still has an appreciable mortality in many parts of the world. Key 
to managing the condition starts with the correct diagnosis. Despite increasing 
recognition of DKA, in particular with the use of the SGLT inhibitors, we still do not 
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Figure 1. A simplified illustration showing the metabolic pathway for 
ketogenesis. During insulin deficiency, glucose uptake into cells is limited, and there 
is a need for an alternative energy substrate. The breakdown of non-esterified fatty 
acids allows the entry of fatty acid CoA to enter the tricarboxylic acid cycle, thus 
generating ATP. However, excess fatty acid CoA production leads to the production 
of acetoacetate (a ketoacid) and beta-hydroxybutyrate (a hydroxyl-acid), causing 
ketoacidosis in periods of extended insulin deficiency. From reference [49]. 
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